Maintaining The Status Quo For ESAs: No Medicare NCD in Renal Disease, CMS Proposes
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite "exhaustive search," CMS has not found the data to set parameters around Medicare coverage for ESAs in the renal setting.
You may also be interested in...
ESA Data On Survival Benefit In Renal Transplant Grafts Are Insufficient - Medicare Panel
The MedCAC review focused narrowly on the benefit of using ESAs - Amgen's Aranesp (darbepoetin alfa) and Centocor Ortho Biotech's Procrit (epoetin alfa) - in transplant graft survival for kidney patients.
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
Although manufacturers and other stakeholders were unable to convince CMS to change its stance on including oral-only drugs to treat end-stage renal disease in a new prospective payment system, the agency's decision to delay that step for three years is being viewed as a somewhat positive result for Amgen and Genzyme in the short term
MedCAC Review Of ESAs In Renal Disease To Help Determine Need For NCD
The Medicare Evidence Development and Coverage Advisory Committee's review of the use of erythropoiesis-stimulating agents in chronic kidney disease is a first step toward determining whether the Centers for Medicare and Medicaid Services should open a national coverage determination process on Medicare payments for such treatment, according to CMS Chief Medical Officer Barry Straube